In vivo immunoimaging of interferon-gamma

Abstract

Methods for in vivo immunoimaging including: (a) administering a labeled-antibody conjugate to a subject, wherein the labeled-antibody conjugate includes: an antibody that specifically recognizes and binds to IFN-γ, and a detection label conjugated to the antibody, wherein the detection label is a radionuclide tracer or fluorophore; and (b) detecting the presence of the radiolabeled-antibody conjugate in the subject in vivo by imaging. Embodiments of the present disclosure are directed to labeled-antibody conjugates and therapeutic radionuclide-antibody conjugates.

1 . A labeled-antibody conjugate comprising:
 an antibody that specifically binds to IFN-γ, and   a detection label conjugated to the antibody, wherein the detection label is a radionuclide tracer.   
     
     
         2 . The labeled-antibody conjugate of  claim 1 , wherein the antibody is isolated. 
     
     
         3 . The labeled-antibody conjugate of  claim 1 , wherein the antibody is selected from a monoclonal antibody, an antibody fragment, or combination thereof. 
     
     
         4 . The labeled-antibody conjugate of  claim 3 , wherein the antibody fragment is a Fab fragment. 
     
     
         5 . The labeled-antibody conjugate of  claim 3 , wherein the antibody fragment is a diabody. 
     
     
         6 . The labeled-antibody conjugate of  claim 1 , wherein the radionuclide tracer is conjugated to the antibody with a bifunctional chelator or linker. 
     
     
         7 . The labeled-antibody conjugate of  claim 6 , wherein the bifunctional chelator comprises a chelator selected from N′-{5-[Acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), 1,4,7-triazacyclononane-N,N′,N′-triacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), ethylenediaminetetraacetic acid (EDTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (i.e., DOPA), diethylenetriaminepentaacetic acid (DTPA), 2,2′-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (NODA), or a combination of any two or more thereof. 
     
     
         8 . The labeled-antibody conjugate of  claim 6 , wherein the bifunctional chelator is p-SCN-Bn-DFO or NOTA. 
     
     
         9 . The labeled-antibody conjugate of  claim 1 , wherein the radionuclide tracer is selected from  11 C,  13 N,  15 O,  18 F,  64 Cu,  68 Ga,  76 Br,  82 Rb,  86 Y,  89 Zr,  99m Tc,  111 In,  124 I,  131 I,  186 Re,  43 K,  52 Fe,  57 Co,  67 CU,  67 Ga,  77 Br,  81 Rb,  81m Kr,  87m Sr,  113m In,  123 1,  125 I,  127 Cs,  129 Cs,  132 I,  197 Hg,  203 Pb,  206 Bi, or a combination of any two or more thereof. 
     
     
         10 . The labeled-antibody conjugate of  claim 1 , wherein the radionuclide tracer is  89 Zr or  18 F. 
     
     
         11 . The labeled-antibody conjugate of  claim 1 , wherein the antibody specifically binds to human IFN-γ.